Shao Shan, Wang Yue, Zhang Nan, Zhao Yan, Zhang Xuelian, Sima Yutong, Wang Ping, Xu Yuan, Wang Tie, Bao Shiping, Cao Yu, Wang Xiangdong, Zhang Luo, Bachert Claus
Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
Department of Otolaryngology Head and Neck Surgery, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):1029-1039. doi: 10.1080/1744666X.2023.2209724. Epub 2023 May 5.
Little evidence exists regarding an integrated multidimensional evaluation methodology to analyze the within-patient effects of medical treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to use an integrated evaluation model to analyze the effects of short-course oral corticosteroid (OCS) followed by intranasal corticosteroid spray (INCS) therapy in patients with severe CRSwNP.
In all, 32 patients with severe CRSwNP received oral methylprednisolone for three weeks followed by intranasal budesonide spray for nine weeks in this prospective single-arm study. An evaluation model integrating the concepts of the core outcome set (COS), clinical control and minimum clinically important difference (MCID) was longitudinally evaluated.
All uncontrolled patients at baseline showed similar progressive improvements from baseline and more than 1 MCID response across core outcomes during the OCS period, with severe CRSwNP being partly controlled in 31 (96.9%) patients and uncontrolled in 1 (3.1%) patient at 3 weeks. During the subsequent INCS period, 14 (43.8%) patients gradually deteriorated to an uncontrolled status at 12 weeks, whereas 18 (56.2%) exhibited partly controlled CRSwNP until 12 weeks.
In more than half of the patients, severe CRSwNP was partly controlled with the initial OCS followed by INCS therapy. An integrated evaluation model was used to facilitate the comprehensive evaluation of within-patient response, especially in patients with different responses to the same treatment.
ChiCTR1900024287.
关于用于分析慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)患者内科治疗的体内效应的综合多维评估方法,现有证据较少。我们旨在使用一种综合评估模型来分析短程口服糖皮质激素(OCS)序贯鼻内糖皮质激素喷雾剂(INCS)治疗对重度CRSwNP患者的疗效。
在这项前瞻性单臂研究中,32例重度CRSwNP患者接受了为期3周的口服甲泼尼龙治疗,随后接受为期9周的鼻内布地奈德喷雾剂治疗。对一个整合了核心结局集(COS)、临床控制和最小临床重要差异(MCID)概念的评估模型进行纵向评估。
所有基线时未得到控制的患者在OCS治疗期间均显示出与基线相比类似的渐进性改善,且在各个核心结局方面均有超过1个MCID的反应,3周时31例(96.9%)患者的重度CRSwNP得到部分控制,1例(3.1%)患者未得到控制。在随后的INCS治疗期间,14例(43.8%)患者在12周时逐渐恶化至未得到控制的状态,而18例((56.2%))患者直至12周时CRSwNP仍处于部分控制状态。
超过半数的患者中,重度CRSwNP通过初始的OCS序贯INCS治疗得到部分控制。使用了一种综合评估模型来促进对患者体内反应的全面评估,尤其是对同一治疗有不同反应的患者。
ChiCTR1900024287。